...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Drug Design, Development and Therapy >An Updated Systematic Review With Meta-Analysis Of Randomized Trials On Topical Cyclosporin A For Dry-Eye Disease
【24h】

An Updated Systematic Review With Meta-Analysis Of Randomized Trials On Topical Cyclosporin A For Dry-Eye Disease

机译：对干眼病局部环孢菌素A的随机试验的荟萃分析更新系统综述

获取原文
   

获取外文期刊封面封底 >>

       
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Background/Aims: To evaluate the effects of topical cyclosporin A (CsA) and artificial tears (ATs) for treating patients with dry-eye disease (DED). Methods: On January 25, 2019, five electronic databases and reference lists were searched for randomized clinical trials (RCTs) comparing CsA with ATs among patients with DED. The search strategy had no restriction on language or time. Two authors extracted surgery, mean age, anesthesia for Schirmer’s test, tear-breakup time, Schirmer’s test score, fluorescein-staining score, ocular surface–disease index, and adverse events. Mean differences (MDs) were calculated for continuous outcomes and Peto ORs for dichotomous data with zero cells. Results were analyzed with 95% CIs in a random-effect model. Results: Eleven RCTs recruiting 1,085 cases with DED were included. Pooled results showed that CsA had better tear-breakup time (MD 0.94, 95% CI 0.08– 1.80), fluorescein-staining score (standardized MD ? 0.72, 95% CI ? 1.28 to ? 0.16), and ocular surface–disease index (MD ? 4.75, 95% CI ? 6.31 to ? 3.18) when compared to ATs. Although CsA had more adverse events than ATs (Peto OR 7.70, 95% CI 3.17– 18.68), no serious adverse events were reported. Conclusion: Overall, CsA is an effective option for treating patients with DED, yet our evidence indicated decreasing effects when CsA was combined with ATs. CsA may be worth suggesting to relatively older patients with DED. We anticipate further RCTs to explore the effects of treatment duration, optimal dosage, and efficacy of CsA in different DED etiology.
机译：背景/目的：评估局部环孢菌素A（CSA）和人工泪液（ATS）治疗干眼症（DED）患者的影响。方法：2019年1月25日，搜索了五项电子数据库和参考列表进行随机临床试验（RCT）将CSA与DED患者患者的ATS进行比较。搜索策略对语言或时间没有限制。两位作者提取手术，平均年龄，沉肠测试的麻醉，撕裂时间，席克斯考试得分，荧光素染色得分，眼部疾病指数和不良事件。为连续结果和PETO或具有零细胞的二分数据计算平均差异（MDS）。在随机效应模型中用95％CI分析了结果。结果：Eleven RCTS招募了1,085例DED案件。汇总结果表明，CSA具有更好的撕裂时间（MD 0.94,95％CI 0.08- 1.80），荧光素染色得分（标准化MD？0.72,95％CI？1.28至0.16）和眼表面疾病指数（与ATS相比，MD？4.75,95％CI？6.31至3.18）。虽然CSA具有比ATS更不良的事件（PETO或7.70,95％CI 3.17-18.68），但没有报告严重的不良事件。结论：总体而言，CSA是治疗DED患者的有效选择，但我们的证据表明当CSA与ATS结合时表明效果降低。 CSA可能值得暗示相对老年患者。我们预计进一步的RCT，以探讨CSA在不同DED病因中的治疗持续时间，最佳剂量和功效的影响。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号